Gebhart G, Keyaerts M, Guiot T, Flamen P, et al. Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. J Nucl Med 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
PMID: 38575192